NCT04282187 2026-03-16Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsUniversity of WashingtonPhase 2 Recruiting25 enrolled
NCT02158858 2025-10-08A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative MalignanciesConstellation PharmaceuticalsPhase 1/2 Completed336 enrolled
NCT04041050 2025-02-14A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmAbbViePhase 1 Active not recruiting85 enrolled
NCT01164163 2014-10-23INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative DiseaseChildren's Oncology GroupPhase 1 Completed49 enrolled